是时候重新考虑如何管理受滑面内质网聚集影响的卵母细胞了吗?
该综述检索至2018年6月1日,纳入21项研究,评估滑面内质网聚集(SERa)对胚胎学和新生儿结局的影响。文献未一致支持SERa与胚胎发生、着床或辅助生殖结局存在负相关。作者建议受精所有成熟卵母细胞,优先移植来自SERa-卵母细胞的胚胎。
要点
- 综述纳入21项研究,未一致支持SERa与胚胎发生、着床或辅助生殖治疗结局存在负相关。
- 作者建议受精所有成熟卵母细胞,优先移植来自SERa-卵母细胞的胚胎。
- 作者认为丢弃SERa+卵母细胞可能不是最符合伦理的方法,即使在大 cohort 取卵日。
核心结论
- 根据现有文献,对SERa+卵母细胞采取个案化注射/授精时机可能无助于胚胎学家决策,作者建议同时受精SERa+和SERa-卵母细胞并优先移植来自SERa-卵母细胞的胚胎。
- 作者认为丢弃SERa+卵母细胞可能不是最符合伦理的方法,即使在大 cohort 取卵日。
- 作者建议所有成熟卵母细胞均可受精,优先移植来自SERa-卵母细胞的胚胎,即使它们来自含SERa+卵母细胞的 cohort;来自SERa+卵母细胞的剩余胚胎可在夫妇知情同意并严格随访妊娠和婴儿的情况下以较低优先级考虑移植。
研究设计与样本
- 本综述文献检索截至2018年6月1日,评估SER形态异常对胚胎学和新生儿结局的影响。
- 纳入标准为前瞻性或回顾性队列研究或病例对照研究,检索Pubmed和Embase数据库,关键词组合为smooth endoplasmic reticulum、SER、oocyte和zygote,纳入英文和人类研究。
主要发现
- 检索共返回726项研究,其中21项符合纳入标准。
- 文献未一致支持SERa与胚胎发生、着床或辅助生殖治疗结局存在负相关。
- 综述研究报告了112例新生儿结局,这些移植中至少一个胚胎来源于受SERa影响的卵母细胞,包括101名健康婴儿、3例活产伴畸形、3例新生儿死亡、1例死产和4例医学终止妊娠。
- 在仅移植来源于SERa+卵母细胞的胚胎后,共报告48名健康新生儿,以及4名围产期并发症婴儿(包括1例室间隔缺损)、1例死产、1例新生儿死亡和1例因多发畸形终止妊娠。
临床怎么用
- 作者建议受精所有成熟卵母细胞,优先移植来自SERa-卵母细胞的胚胎,即使它们来自含SERa+卵母细胞的 cohort。
- 作者认为来自SERa+卵母细胞的剩余胚胎可在夫妇知情同意并严格随访妊娠和婴儿的情况下以较低优先级考虑移植。
- 作者认为丢弃SERa+卵母细胞可能不是最符合伦理的方法,即使在大 cohort 取卵日。
局限性
- 本综述受纳入研究质量的限制,特别是可能存在方法学局限、样本量有限和研究为回顾性。
- 21项入选研究中,7项为摘要,2项为病例报告;其余14项研究中仅3项为前瞻性。
- 识别SERa+卵母细胞的工具可能因研究而异,不能排除 consequent 误分类。
- 考虑到光学显微镜检测SER聚集的分辨率较差,作者不确定 apparently SERa-卵母细胞在电子显微镜或 time lapse 系统分析下是否真的不表现出这种形态异常。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Did the revised Alpha/ESHRE consensus (Vienna, 2017) bring a real answer on managing oocytes with aggregates of smooth endoplasmic reticulum (SERa)? SUMMARY ANSWER: According to the currently available literature, a case by case approach on the time of injecting/inseminating SERa+ oocytes may be not helpful for embryologists making a decision, so we suggest fertilizing both SERa+ and SERa- oocytes and prioritizing embryos derived from SERa- oocytes. WHAT IS KNOWN ALREADY?: In 2011, the Istanbul consensus recommended not to inject/inseminate SER+ oocytes due to adverse foetal outcomes reported in literature. At the end of 2017, a panel of experts reconsidered this recommendation and advised a case by case approach. Hence, with a lack of clear recommendations, in-vitro fertilization practitioners still have heterogeneous attitudes when managing SERa+ oocytes. In this context of controversy, an updated review could be helpful in (i) forming a common language for managing cases of SERa+ oocytes and (ii) offering the most ethical practice and best care for patients seeking infertility treatment or fertility preservation. STUDY DESIGN, SIZE, DURATION: This review (with a last literature search on 1 June 2018) evaluated the effect of the SER dysmorphism on embryological and neonatal outcomes. PARTICIPANTS/MATERIALS, SETTING, METHODS: Studies were considered for inclusion if they were prospective or retrospective cohort or case-control studies. Electronic searches of the Pubmed and Embase databases were done using the keyword combination: smooth endoplasmic reticulum, SER, oocyte and zygote. Abstracts and articles written in English and limited to humans were included. MAIN RESULTS AND THE ROLE OF CHANCE: The search returned a total of 726 studies among which 21 met the inclusion criteria. The literature does not unanimously support a negative association between SERa and embryogenesis, implantation or assisted reproductive therapy outcomes. The reviewed studies reported 112 neonatal outcomes after transfers where at least one embryo originated from oocyte affected by SERa. They included 101 healthy babies, three live births with malformations, three neonatal deaths, one stillbirth and four medical interruptions of pregnancy. After transfer of embryos exclusively derived from SERa+ oocytes, a total of 48 healthy newborns were reported along with four babies with perinatal complications (including one ventricular septal defect), one stillbirth, one neonatal death and one pregnancy termination for multiple malformations. LIMITATIONS, REASONS FOR CAUTION: As with any review, this review was limited by the quality of the included studies especially in terms of possible methodological limitations, the limited sample size and the retrospective aspect of the studies. Among the 21 selected studies, seven were abstracts and two were case reports. Of the remaining 14 studies, only three were prospective. The tools used in identifying SERa+ oocytes may have varied from one study to another and a consequent misclassification cannot be excluded. Considering the poor resolution of light microscopy in detecting SER aggregates, we are not sure that apparently SERa- oocytes do not really exhibit such a dysmorphism if they were analysed under electronic microscopy or a time lapse system. WIDER IMPLICATIONS OF THE FINDINGS: In the light of the existing data and the lack of a real link between fertilizing SERa+ oocytes and the occurrence of embryo aneuploidy/malformations, we think that discarding SERa+ oocytes may be not the most ethical approach even in patients with large cohorts on the day of oocyte retrieval. Avoiding the wastage of oocytes and embryos with respect to medical ethics remains a constant concern in daily IVF practice. Thus, we recommend that all mature oocytes could be fertilized and embryos originating from SERa- oocytes would be preferably transferred, even if they come from a cohort with SERa+ oocytes. The remaining embryos derived from SERa+ oocytes could be considered with a lower priority for transfer after obtaining consent from the couple if a strict follow-up of the pregnancy and the baby is performed. STUDY FUNDING/COMPETING INTEREST(S): We have no conflict of interest to declare and no funding was received. REGISTRATION NUMBER: N/A.
引用
- Ferreux L, Sallem A, Chargui A, et al. Is it time to reconsider how to manage oocytes affected by smooth endoplasmic reticulum aggregates? Hum Reprod. 2019. PMID: 30805638. doi:10.1093/humrep/dez010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。